NORMAN, OK–(Marketwire – August 12, 2010) – Access Plans, Inc. (OTCBB: APNC), a leading membership benefits marketing company, today announced that the Company will host an investor conference call to discuss its operating results for the third quarter and first nine months of FY2010 at 11:30 a.m. Eastern Time (EDT) on Monday, August 16, 2010. The Company will release its operating results earlier the same day.

Shareholders and other interested parties may participate in the conference call by dialing 877-317-6789 (international/local participants dial 412-317-6789) and asking to be connected to the “Access Plans, Inc. Conference Call” a few minutes before 11:30 a.m. EDT on August 16, 2010. The conference call will also be available via “live” webcast under the Investor Relations section of the Company’s website at www.accessplans.com, or by visiting http://www.videonewswire.com/event.asp?id=71766  to access the webcast directly.

A replay of the conference call will be available one hour after the call through Tuesday, August 24, 2010 at 9:00 a.m. EDT by dialing 877-344-7529 (U.S.) or 412-317-0088 (international) and entering the conference ID Number 443633.

An archived version of the webcast will also be available under the Investor Relations section of the Company’s website at www.accessplans.com.

About Access Plans, Inc.

Access Plans, Inc. (OTCBB: APNC) is a leading membership benefits marketing company with two distribution channels. The Wholesale/Retail Plans distribution channel specializes in turnkey, private-label membership benefit plans that provide discount products and services, protection benefits and retail services to more than 1 million customers in the United States and Canada. America’s Health Care Plans (AHCP), the Company’s Insurance Marketing distribution channel, is one of the nation’s largest independent agent networks and provides major medical, life and supplemental insurance products to individuals. For more information, please visit: www.accessplans.com.

LAGUNA HILLS, CA–(Marketwire – August 11, 2010) –  Today, Iconosys, Inc., a leader in mobile communications technology, announces a first in terms of integrating the world’s primary new means of communication, text messaging, with the needs of professionals in Real Estate, Medical Offices, Dental Offices, and for appointment setters of all types.

Originally a research and development project designed to explore possibilities and further enhance the wildly popular texting while driving apps already offered by Iconosys’ SMS Replier™ (www.smsreplier.com) and DriveReply™ (www.drivereply.net) products, Mighty SMS™ has now evolved into a text message scheduling system that allows professionals to setup reminders for their clients and patients and enables them to send their clients and customers friendly courtesy notices/reminders prior to their scheduled meetings and thank you notes afterward.

Mighty SMS™ comes in a personal version, where all features are managed on the phone itself, or in a professional version with more functionality; the app can be administered through an internet interface, and scheduling can be done in real time (right in front of the patient, or while on the phone with a sales lead) and as your appointments are being scheduled. The web interface/management comes at a nominal monthly fee. Also, while the company is excited about its plans for integration of this app into Google Calendar and Outlook in the near future as a plug-in for ease of management by office staff and appointment setters, at present Mighty SMS™ is fully functional and ready to meet the heavy demands of the busy professional or house-spouse.

As of now, a personal user can use it to pre-program text message salutations to their friends, loved ones, and professional contacts. Thank You’s, Happy Birthday’s, and Happy Anniversary’s are not accidentally forgotten when you input your Mighty SMS™ onto your phone and utilize this to organize your calendar and your contacts.

In the Professional version, customized replies can be generated that remind clients and patients of upcoming appointments, with information about contacting you back if there are any changes. 

“Already a favorite among dentists here in Orange County, CA, the dentists are seeing a lower volume of cancellations and ‘forgetting’s,’ as patients that made appointments sometimes months earlier, and may have completely forgotten their appointment, get a friendly non-threatening personal message from their favorite service provider (dentist, doctor, optometrist, hairstylist, chiropractor, contractor, MONAVIE rep, etc.),” commented Wayne Irving, CEO of Iconosys, Inc. Mr. Irving continued, “It’s great for car salesmen or others in sales that want to pre-program a thank you message for a couple days later after the sale, to send good wishes and work for that return customer and high rating of customer satisfaction.”

Texting or text messaging has become a significant portion of our population’s first means of communication. Less formal than an email, more convenient than a phone call or voicemail, and more secure than instant messaging, text messaging has become our tool for meaningful introductions when two people wish to express or share short messages without getting into deep conversations, for reasons like lack of time, while still providing a sense of personal fulfillment and significance to the recipient for the “thought that counted” when they receive a wish for good tidings.

Text messaging is a great way to share short personal bits of data between people that share responsibilities, like parents and or partners in a company. It’s a great way to send addresses and other short bits of info that do not require a full conversation, and without the risk of leaving a voicemail that may not get listened to for days and days.

“I use text messaging for every possible communication I can. It allows me to talk to more people, get more done in less time, and keep tabs on my employees, without having to go through all the greetings and salutations and small talk all the time. I don’t do it ALL the time, but it sure helps me to build my business and be more productive wherever I am, while also allowing me to regularly and consistently stay in touch with the people I work with and to convey a ‘job-well-done’ or to give them constructive advice where appropriate,” said Jeffrey Weiss, CTO for Iconosys, Inc.

Mighty SMS™ is available to the personal User for $3.99 per month, and for the Business or Professional user at $59.99 per year. The integrated web interface tools are scheduled to be made available in September for Professional users only at a $39 per month maintenance fee. Professional users price includes 60 minutes of tech support per year for setup, changes, and migration advice. The service currently requires a Windows Mobile 6.5 or Windows Phone 7. The company plans to offer this product on the Android platform when the Android Tablet is released closer to Christmas 2010.

Mighty SMS™ is pending availability on the Windows Marketplace, but until then it can be downloaded from www.Handango.com, www.CNET.com, www.PayLoadz.com and www.MightySMS.com.

About Iconosys, Inc.

Iconosys, Inc. is developing a series of technologies designed to make mobile applications better, faster, easier, and ultimately safer to use. Iconosys’ flagship product, SMS Replier™, is a revolutionary mobile phone application designed to couple many convenience services with addressing the growing problem of communicating safely while driving a car, truck, or motorcycle.

Iconosys’ CEO Wayne Irving II, a pioneer in next-generation telecom concepts, has led the drive to take advantage of GPS and other onboard motion technologies to build lifesaving and life-enhancing products and utilities, and to create new and better tools for wireless platforms and mobile device operating systems.

Iconosys proprietary technology, developed with support from Motorola, is a complex series of algorithms and readings from the technology running on today’s Smartphones; this includes, without limitation, GPS and other motion sensoring, coordinated with Google mapping to provide an accurate and responsive background service to most, if not all, of the upcoming Iconosys technology releases. Iconosys’ DriveReply™ technology tests up to 90% more efficient in battery consumption while using ordinary GPS technology, a key differentiator for Iconosys, when competing with other producers of GPS dependent Smartphone applications. 

For more information, including demonstration videos, on Iconosys, Inc, please visit: http://www.iconosys.com or http://www.mightysms.com. 

For further information about Iconosys, Inc. and its products or for interviews with CEO Wayne Irving II, please contact Adam Mazur at 212-843-8073 or [email protected]. High-resolution images and instructional videos available upon request. Follow Mighty SMS™ on twitter: @mightysms

Click here to see all recent news from this company

SAN JOSE, CA–(Marketwire – August 11, 2010) –  Beginning on September 23^rd, the Patient Protection and Affordable Care Act will allow consumers who purchase new or revised insurance plans or policies to receive an array of preventive care services with no out-of-pocket cost. The Foundation for Health Coverage Education (FHCE), www.CoverageForAll.org, while applauding any efforts to keep overall health care costs down, cautions that this provision could instead lead to out-of-control medical costs which will escalate insurance premiums.

“While mammograms and colonoscopies clearly provide preventive services that are cost-effective and can save lives, one has to question the government’s waiving the total cost to the consumer for smoking cessation, and weight loss and alcohol treatment, which are included in these mandated services. A line must be drawn by the government as to where its funding ends and where personal responsibility begins,” said Phil Lebherz, FHCE Founder and Executive Director. 

“Behavior modification programs represent a billion dollar industry with high recidivism rates. As a result, because they will be available at no cost, enrollments in programs to combat the effects of lifestyle diseases from smoking, obesity and alcoholism will ratchet up costs with little expectation that the consumer be responsible for making healthy lifestyle choices,” said Lebherz.

The new law will require that individual policies and employer-based health plans offer certain mandated preventive health care services with no out-of-pocket costs to Americans
when they enroll in either new individual health policies or new group health plans. Going forward, the consumers with the new policies or plans will not be charged a co-payment, coinsurance or deductible for certain preventive services performed by a network provider, doctor or testing service, covered under their policy. Consumers who keep their grandfathered plans and do not change their existing individual coverage or whose employer-based group plans are not changed considerably, won’t be eligible for mandated services that have no cost out-of-pocket expenses. 

“The government cannot legislate personal responsibility,” Lebherz said. “If it’s free, it will increase costs and accomplish little because people in counseling for obesity, alcohol, and or smoking sensation tend to backslide and readmit to programs. In fact, new policies will cost more than the grandfathered policies.”

Mandates can provide a greater range of care, but they also mean increased premiums as insurers must cover out-of-pocket costs that were originally paid by consumers. The accumulation of mandates plays an important role in raising costs. According to the Council for Affordable Health Insurance (CAHI), there are over 2,000 mandated benefits. CAHI’s studies show that mandated benefits could increase the cost of basic coverage from approximately 20% to as much as 50%, depending on the number and design of the benefits, as well as the initial cost of the premium.

“It’s important for everyone to have adequate health coverage, but we have to draw the line somewhere,” said Lebherz. “Making healthy personal lifestyle choices are within the reach of all of us,” said Lebherz.

Launched in 2004, CoverageForAll.org is America’s first public health insurance search engine, helping over two million Americans discover their public and low-cost private health insurance options. Every month 70,000 people visit the website or call the free 24/7 multilingual U.S. Uninsured Help Line (800-234-1317) to take the simple 5-question Health Coverage Eligibility Quiz and speak with a live health insurance specialist who can walk them through the process, connect them with the programs and applications and provide them with a sign-up checklist needed to successfully apply. 

For information regarding health insurance and health care reform changes, please visit www.CoverageForAll.org or call the toll-free 24/7 U.S. Uninsured Help Line 800-234-1317. The Foundation for Health Coverage Education is a 501 (c) 3 national non-profit organization with a mission to provide simplified public and private health insurance eligibility information in order for more people to access coverage.

Click here to see all recent news from this company

AUSTIN, TX–(Marketwire – August 11, 2010) –  Crossroads Systems, Inc. (PINKSHEETS: CRDS), a global provider of solutions to connect, protect, secure and restore data, today announced a global reseller alliance with Dell Services.

As healthcare providers recognize the importance of healthcare IT in providing high-quality patient care, a growing number of healthcare organizations worldwide are implementing MEDITECH healthcare information system (HCIS) applications. Dell Services works closely with healthcare organizations to optimize the long-term use of the MEDITECH system and improve healthcare delivery. In fact, Dell has received top recognition in the clinical systems sector. According to Gartner, Dell is ranked #1 for IT Services in the worldwide healthcare market, based on 2009 revenue. The company was also listed in Healthcare Informatics’ Top 100 Healthcare IT Companies.

With a growing emergence of patient privacy rights and other compliance requirements, the healthcare delivery landscape is rapidly changing, putting new pressures on IT to include fully-integrated data protection, privacy and security solutions within their MEDITECH environment.

Under this new alliance, MEDITECH customers will be offered Crossroads’ products — starting with Crossroads TapeSentry and SPHiNX solutions, which have been certified by Dell Services for MEDITECH, to take advantage of key data protection features such as efficient virtual tape backup, powerful encryption, and replication technologies. These offerings include:

TapeSentry as an appliance solution providing secure tape encryption using a robust key management system.

SPHiNX as a dedicated virtual tape appliance offering optimized data protection and resiliency for Windows server environments.

“Crossroads’ solutions continue to attract organizations within highly sensitive industries such as healthcare and finance,” said Rob Sims, President and CEO of Crossroads Systems. “Through our reseller alliance with Dell Services, we can extend our reach of the Crossroads’ SPHiNX and TapeSentry solutions within clinical environments worldwide — where data privacy, protection and security are of the upmost importance.”

“Information Technology is integral to improved patient safety and quality of care. As the HIPAA Act, and more recently, the HITECH ACT attest, safeguarding electronic protected health information must be every healthcare executive’s priority. The partnership of Dell Services and Crossroads is uniquely positioned to bring cost-effective, proven data protection solutions to a large segment of the MEDITECH community,” said John Ebel, Senior Manager, MEDITECH Solutions Group, Dell Services.

About DELL
Dell Inc. (NASDAQ: DELL) listens to customers and delivers worldwide innovative technology and business solutions they trust and value. Dell Services develops and delivers a comprehensive suite of services and solutions in applications, business process, consulting, infrastructure and support to help customers succeed.

Dell is a trademark of Dell Inc.

About Crossroads Systems
Headquartered in Austin, Texas, Crossroads Systems, Inc. is a leading provider of solutions to connect, protect, secure and restore data. Crossroads (PINKSHEETS: CRDS) trades over-the-counter on Pink Sheets and posts its financial disclosure reports, press releases and other related documentation on the OTCIQ Web service of the Pink Sheets Web site. Visit www.crossroads.com.

Forward-Looking Statements
This release may include forward-looking statements. The words “believe,” “expect,” “intend,” “plan,” “project,” “will” and similar phrases as they relate to Crossroads are intended to identify such forward-looking statements. These statements reflect the current views and assumptions of Crossroads and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations.

©2010 Crossroads Systems, Inc. Crossroads and Crossroads Systems are registered trademarks of Crossroads Systems, Inc. All specifications are subject to change without notice.

Click here to see all recent news from this company

BURBANK, CA–(Marketwire – August 11, 2010) –  Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that on Thursday August 12, 2010 at 1:00pm PST, (4:00pm EST) the company’s CEO, Mr. Dean Janes, will be hosting a conference call. To join the conference call, please call 1-888-373-5705 and enter passcode 364039 followed by the pound sign (#). You will be connected to the conference call in a listen only mode, and then lines will be opened for questions following the presentation.

The purpose of the call is to update Shareholders and other interested parties of the current developments with the company.

A limited number of lines will be available for this conference call. The lines will open up 5 minutes prior to the start of the call.

A recording of the conference call will be made available on the company’s website as soon as it is available. Imaging3 will notify shareholders and others who subscribe to the company newsletter. Anyone who would like to be added to this list is encouraged to sign-up for the e-mail based newsletter on the company’s website using the following link — http://www.imaging3.com/newsletters_signup.html.

About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at http://www.imaging3.com for more information.

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction and potential product liability claims, and other factors detailed in reports filed by the Company.

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Aug. 10, 2010) –

(NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA)

Medifocus Inc. (TSX VENTURE:MFS)(PINK SHEETS:MDFZF) (“Medifocus” or the “Company”) announces the completion of a private placement of 2,449,997 Units (the “Units”) at a price of $0.30 per Unit for gross proceeds of $734,999. Each unit is comprised of one Common Share and one Series A Common Share purchase warrant. Each Series A Common Share purchase warrant will entitle the holder to purchase one additional Common Share at a price of $0.50 for a period of 24 months following the closing of the offering. If, at any time prior to April 26, 2012, the daily volume weighted average trading price of the Company’s common shares on the TSX Venture Exchange exceeds $0.75 for at least 10 consecutive trading days, the Company may, within 30 days of such occurrence, give an expiry acceleration notice to the holders of warrants and, if it does so, the warrants will, unless exercised, expire on the 30th day after the expiry acceleration notice is given.

Securities issued in connection with the private placement and any shares issued upon the exercise of the warrants will have a hold period in Canada until December 7, 2010.

The net proceeds of this offering will be primarily used to initiate a pivotal phase III clinical trial using the Company’s Microfocus APA 1000 System for the treatment of breast cancer (including all related professional expenses) and for working capital.

Medifocus also announces that it is in the process of finalizing the previously announced debt settlement with certain third party creditors, employees and service providers. Subject to approval by the TSX Venture Exchange, Medifocus will issue an aggregate of 3,592,105 common shares at an aggregate deemed price of $0.50 per common share to settle such outstanding debt. The common shares issued will be subject to hold periods pursuant to applicable securities laws as well as the policies of the TSX Venture Exchange.

Medifocus owns a patented microwave focusing technology platform (the Adaptive Phased Array (“APA”) technology), which can precisely target and control microwave energy to cause heating in cancerous tumors anywhere in the body reliably and repeatedly. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness and reduced toxicity and to trigger the targeted release of therapeutic drugs and genes at tumor sites at lower temperatures. While the core technology has been licensed from the Massachusetts Institute of Technology, Medifocus has further refined the precision of the microwave focusing and control ability and developed a commercial system dedicated exclusively for the treatment of Breast Cancer. Please visit www.medifocusinc.com for more details.

COLD SPRING, NY–(Marketwire – August 10, 2010) –  Though it sounds strange enough, the “stickiness” of your medical website is critical to its ultimate success. It is the way you get visitors to your site, keep them there and get them to return over and over. “Your website needs to make a good impression in order for your potential patients to spend more than 30 seconds on it,” said Daniel Gilbert, CEO of Aurora Information Technology (Aurora IT), a medical website design and physician marketing company based in Cold Spring, New York.

“The challenges in medical website marketing are endless,” explains Gilbert. “First, you have to build your site and get traffic to it. Then you have to keep them there and not click away after a few seconds thinking there is nothing there for them. Stickiness is what makes visitors into patients.”

And how is “stickiness” accomplished? Gilbert believes a good Content Management System (CMS) is vital, such as the Bitrix Site Manager that they employ in their website designs. Aurora IT is a Certified Gold Bitrix Partner and they stand behind the offerings of the product to improve a site’s traffic. “Bitrix CMS includes a series of building blocks that perform certain functions, such as blogs, calendars, newsletters, etc.,” said Gilbert, “But the Bitrix CMS goes a step beyond with features and functions that can make your medical website sticky, interactive and functional.”

Gilbert offers these CMS offering basics and value-added extras that can optimize your website’s stickiness and make it attractive to current and future patients:

Content: Relevant and updated content is the most important factor in attracting visitors. For doctors, medical condition, treatment and practice information communicate value to your visitors.

Photo Gallery: People in search of medical information are visual creatures and appreciate quality photographs, especially before and after photos and pictures of conditions and outcomes. Be sure not to have too many graphics or photos that are heavy and slow to load because most patients are not patient.

Social Networking: In addition to Facebook or Twitter, your medical website can feature social networking via forums and message boards that allow your visitors to make contributions to the site by providing comments and participating in discussions. Building community is excellent marketing.

Newsletters: Newsletters bring return visitors and are an effective form of e-marketing. They should contain useful, relevant information as well as possible promotions. Be sure to have visitors opt-in and allow them to unsubscribe easily or you will damage your reputation.

Events Calendar: Put information seminars, patient related events, workshops and more on an event calendar. Your visitors will see the value-add and you will drive more traffic not only to your site but also to your practice.

Media Player: Video and audio give your patients a dynamic, interactive experience. You can feature promotions, provide tutorials and introduce your practice to patients. The engaging nature of video and audio encourages users to spend more time on a page and help you “upsell,” because these clips can relay more essential information in less time.

“Website stickiness gets potential patients to stay and explore everything relevant to them in your website,” concluded Gilbert. “It incites them to read, interact, sign up, give feedback, and transform them from a casual surfer into a repeat visitor and future patient.”

Click here to see all recent news from this company

WEST PALM BEACH, FL–(Marketwire – August 10, 2010) – HearUSA, Inc. (NYSE Amex: EAR), a
leader among the nation’s hearing care providers, reported financial
results for the second quarter ended June 26, 2010.

Financial Results for Second Quarter 2010

In the second quarter of 2010, net revenues increased 9% to $21.4 million
from $19.6 million in the previous quarter, but decreased 6% from $22.7
million in the second quarter of 2009. The decrease year-over-year was
principally the result of some insurance plans eliminating, changing or
limiting their hearing care benefits at the beginning of 2010. The company
implemented a number of plans and strategies during the first quarter of
2010 which helped to replace most of the lost insurance business, including
increased marketing to its existing insurance base and private pay
customers. The company also increased the marketing of its AARP Hearing
Care Program and made it available to AARP members in 45 states through all
177 HearUSA centers and a network of independent AARP Hearing Care Program
providers. These combined efforts were the primary cause of the 9% increase
in second quarter revenue over the previous quarter.

The loss from continuing operations totaled $1.9 million in the second
quarter of 2010, compared to a loss of $2.5 million in the previous
quarter, and income of $963,000 in the second quarter of 2009. The loss
from continuing operations includes AARP advertising costs of $957,000
incurred in the second quarter of 2010 compared to $253,000 in the previous
quarter and none incurred in the second quarter of 2009. Advertising,
royalties and administrative costs associated with the AARP program totaled
$1.3 million in the second quarter of 2010, $588,000 in the previous
quarter and $142,000 in the second quarter of 2009.

Net loss attributable to common stockholders was $2.2 million or $(0.05)
per basic and diluted share in the second quarter of 2010, as compared to a
net loss of $2.7 million or $(0.06) per basic and diluted share in the
previous quarter of 2010, and net income of $1.1 million, or $0.03 per
basic and $0.02 per diluted share, in the same year-ago period. Net loss
attributable to common shareholders in the second quarter of 2009 included
income from discontinued operations of $336,000 or $0.01 per basic and
diluted share.

Management Commentary

“Our focus during the second quarter of 2010 was to increase revenues to
offset the loss of the managed care business in the first quarter and to
expand the reach of the AARP program,” said Stephen Hansbrough, CEO and
chairman of HearUSA. “The 9% increase in revenues over the first quarter of
2010 and the successful launch of the AARP program to AARP members in a
total of 45 states has given us a strong base for continued success going
into the third quarter.

“We have seen appointments grow at an accelerating pace since we launched
our AARP national advertising campaign, and AARP included the HearUSA
program in its publications and web sites in the latter half of the second
quarter. We expect this momentum to continue and believe that center
revenues will grow between 9% and 15% in the second half of 2010 when
compared to the first half, and our target is to grow center revenues 15%
to 20% in 2011 when compared to 2010.

“We will focus primarily on expanding the number of independent providers
participating in the AARP network during the rest of 2010 and expect to
have more than 800 participating providers by the end of the year,”
continued Mr. Hansbrough. “Both HearUSA and AARP will also continue to
increase awareness and member communications during the remainder of the
year. We believe that it will take time to fully develop the provider
network and educate the AARP membership base. Our targets for 2011 are to
expand the AARP network to more than 2,000 participating providers and
generate AARP network sales of over 30,000 units.”

Conference Call

HearUSA will hold a conference call at 4:30 p.m. Eastern time, August 10,
2010, to discuss its second quarter 2010 financial results. The company’s
senior management will host the presentation, which will be followed by a
question and answer period.

To participate in the call, dial the appropriate number 5-10 minutes prior
to the start time, request the HearUSA conference call and provide the
conference ID: 7HEARUSA.

Date: Tuesday, August 10, 2010
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Domestic callers: 1-800-862-9098
International callers: 1-785-424-1051
Conference ID#: 7HEARUSA

A Web simulcast and replay will be available via the investor relations
section of the company’s website at www.hearusa.com.

If you have any difficulty connecting with the conference call or webcast,
please contact the Liolios Group at 1-949-574-3860.

A telephone replay of the call will be available later that evening and
will be accessible until August 17, 2010:

Toll-free replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Replay Pin Number: 11721

About HearUSA

HearUSA is the recognized leader in hearing care for the nation’s top
managed care organizations through its 177 company-owned centers and
network of more than 2,000 hearing care providers. HearUSA is the nation’s
only hearing care provider accredited by URAC, an independent, nonprofit
health care accrediting organization dedicated to promoting health care
quality through accreditation, certification and commendation. HearUSA is
also the administrator of the AARP Hearing Care Program, designed to help
millions of Americans aged 50+ who have untreated hearing loss. For more
information about HearUSA visit www.hearusa.com, or go to
www.hearingshop.com for a wide selection of hearing related products
available for purchase online.

Forward Looking Statements

This press release contains forward-looking statements within the meaning
of the Securities Litigation Reform Act of 1995, including those statements
that HearUSA plans to expand its AARP program to include more than 800
participating independent hearing care providers during the course of 2010
and over 2,000 participating providers in 2011; that the company expects
second quarter 2010 momentum to continue; that the company believes that
center revenues will grow between 9% and 15% in the second half of 2010
when compared to the first half of 2010; that the company’s target is to
grow revenues 15% to 20% in 2011 when compared to 2010; and that the
company plans to generate AARP network sales of over 30,000 units. These
statements involve certain risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking statements.
Potential risks and uncertainties include such factors as the company’s
continuing ability to replace lost and decreased revenue from insurance
contracts with increased self-pay revenue, replacement insurance agreements
and other revenue; the company’s ability to attract and retain a sufficient
number of independent providers in all 50 states to participate in the AARP
program; the company’s ability to successfully integrate the AARP program
into its company-owned centers; the ability of the Company to capitalize on
the advertising efforts for the AARP program; the company’s ability to
control costs; the company’s ability to generate sufficient cash flows to
fund its various advertising campaigns; the ability of the company to
maintain unit sales of Siemens hearing aids; market demand for the
company’s goods and services; changes in the pricing environment; general
economic conditions in those geographic regions where the company’s centers
are located; consumer confidence in the general economy; the impact of
competitive products; and other risks and uncertainties described in the
company’s filings with the Securities and Exchange Commission, including
the company’s Form 10-K for the fiscal year ended December 26, 2009.

                               HearUSA, Inc.
                  Consolidated Statements of Operations
            Three Months Ended June 26, 2010 and June 27, 2009
                                (unaudited)


                                                 June 26,       June 27,
                                                   2010           2009
                                               ------------   ------------
                                                 (Dollars in thousands,
                                                except per share amounts)

Net revenues
Hearing aids and other products                $     19,796   $     20,653
Services                                              1,613          2,014
                                               ------------   ------------
Total net revenues                                   21,409         22,667
                                               ------------   ------------

Operating costs and expenses
Hearing aids and other products                       5,290          5,072
Services                                                412            388
                                               ------------   ------------
Total cost of products sold and services
 excluding depreciation and amortization              5,702          5,460

Center operating expenses                            12,209         10,908
General and administrative expenses                   3,769          3,661
Depreciation and amortization                           564            588
                                               ------------   ------------
Total operating costs and expenses                   22,244         20,617
                                               ------------   ------------
Income (loss) from operations                          (835)         2,050
Non-operating income (expenses)
Gain (loss) on foreign exchange                          (5)           375
Interest income                                           5              -
Interest expense                                       (841)        (1,252)
                                               ------------   ------------
Income (loss) from continuing operations
 before income tax expense                           (1,676)         1,173
Income tax expense                                     (220)          (210)
                                               ------------   ------------
Income (loss) from continuing operations             (1,896)           963
Discontinued operations attributable to
 HearUSA, Inc.
Income from discontinued operations, net of
 income tax benefit of $270 in 2009                       -            250
Gain on sale of discontinued operations                   -          1,632
Income tax expense on sale of discontinued
 operations                                               -         (1,546)
                                               ------------   ------------
Income from discontinued operations                       -            336
                                               ------------   ------------
Net income (loss)                                    (1,896)         1,299

Net income attributable to noncontrolling
 interest                                              (238)          (131)
                                               ------------   ------------
Net income (loss) attributable to HearUSA,
 Inc.                                                (2,134)         1,168
Dividends on preferred stock                            (32)           (35)
                                               ------------   ------------

Net Income (loss) attributable to HearUSA,
 Inc. common stockholders                      $     (2,166)  $      1,133
                                               ============   ============

Loss from continuing operations attributable
 to HearUSA, Inc. common stockholders per
 common share - basic                          $      (0.05)  $       0.02
                                               ============   ============
Loss from continuing operations attributable
 to HearUSA, Inc. common stockholders per
 common share - diluted                        $      (0.05)  $       0.02
                                               ============   ============

Net loss attributable to HearUSA, Inc. common
 stockholders per common share - basic         $      (0.05)  $       0.03
                                               ============   ============
Net loss attributable to HearUSA, Inc. common
 stockholders per common share - diluted       $      (0.05)  $       0.02
                                               ============   ============

Weighted average number of shares of common
 stock outstanding - basic                           44,922         44,837
                                               ============   ============

Weighted average number of shares of common
 stock outstanding - diluted                         44,922         45,340
                                               ============   ============

Amounts attributable to HearUSA, Inc. common
 stockholders:

Income (loss) from continuing operations, net
 of tax                                        $     (2,134)  $        832
Discontinued operations, net of tax                       -            336
                                               ============   ============

Net income (loss) attributable to HearUSA,
 Inc. common stockholders                      $     (2,134)  $      1,168
                                               ============   ============





                               HearUSA, Inc.
                        Consolidated Balance Sheets
                                (unaudited)


                                                 June 26,     December 26,
ASSETS                                             2010           2009
                                               ------------   ------------
                                                 (Dollars in thousands,
                                                except per share amounts)
Current assets
Cash and cash equivalents                      $      4,026   $      7,037
Short-term marketable securities                      1,306          4,106
Accounts and notes receivable, less allowance
 for doubtful accounts of $677 and $616               5,506          5,554
Inventories                                           1,409          1,844
Prepaid expenses and other                              417            464
                                               ------------   ------------
Total current assets                                 12,664         19,005
Property and equipment, net                           3,463          4,021
Goodwill                                             51,928         51,495
Intangible assets, net                               12,529         12,816
Deposits and other                                      698            731
Restricted cash and cash equivalents                  3,252          3,245
                                               ------------   ------------
Total Assets                                   $     84,534   $     91,313
                                               ============   ============

LIABILITIES AND STOCKHOLDERS'  EQUITY
Current liabilities
Accounts payable                               $      9,458   $      7,070
Accrued expenses                                      1,907          2,253
Accrued salaries and other compensation               3,224          3,520
Current maturities of long-term debt                  5,357          5,983
Income taxes payable                                      -          1,974
Dividends payable                                        35             35
                                               ------------   ------------
Total current liabilities                            19,981         20,835
                                               ------------   ------------
Long-term debt                                       33,781         36,139
Deferred income taxes                                 7,775          7,335
                                               ------------   ------------
Total long-term liabilities                          41,556         43,474
                                               ------------   ------------
Commitments and contingencies
                                               ------------   ------------

Stockholders' equity
Preferred stock (aggregate liquidation
 preference $2,330, $1 par, 7,500,000 shares
 authorized)
Series H Junior Participating
 (none outstanding)                                       -              -
Series J (233 shares outstanding)                         -              -
                                               ------------   ------------
Total preferred stock                                     -              -

Common stock: $.10 par; 75,000,000 shares
 authorized 45,451,160 and 45,381,750 shares
 issued                                               4,545          4,538
Additional paid-in capital                          138,359        137,863
Accumulated deficit                                (119,804)      (114,982)
Treasury stock, at cost: 523,662 common shares       (2,485)        (2,485)
                                               ------------   ------------
Total HearUSA, Inc. Stockholders' Equity             20,615         24,934

Noncontrolling interest                               2,382          2,070
                                               ------------   ------------
Total Stockholders' equity                           22,997         27,004
                                               ------------   ------------
Total Liabilities and Stockholders' Equity     $     84,534   $     91,313
                                               ============   ============

PHOENIX, AZ–(Marketwire – August 10, 2010) –  VALLEYLIFE, a not for profit organization committed to serving individuals with developmental disabilities, launched a sponsorship program to benefit its disabled members and invites the public to attend an open house. For more than 63 years, VALLEYLIFE has provided services to its disabled members so they might not only meet daily essential needs, but to achieve a brighter future with programs that support job training, housing, social activities, and independent living skills. 

Due to a recent termination in state funding, more than 700 disabled citizens in Arizona have been cut from their programs. At VALLEYLIFE, 17 members are directly affected and no longer receive government funding. Despite this, the staff at VALLEYLIFE has continued to provide its members the ongoing support they need. 

“Most of the members directly affected have no family. The staff at VALLEYLIFE has become their family and they, a part of ours. We will continue to provide the programs as long as we can, but without appropriate services, some of our disabled members may end up on the street or in jail,” said Cletus Thiebeau, CEO of VALLEYLIFE.

VALLEYLIFE’s sponsorship program enables local business and private citizens an opportunity to support the community they live in by providing our members with services they need to be independent. The cost to sponsor a member for one hour of service is $4, the cost of a gourmet cup of coffee. The programs range from vocational services where a member is able to earn money, to day treatment program services, where a developmentally disabled member is under the care of a qualified staff member.

VALLEYLIFE prides itself in its low administrative cost of 7 percent; 93 cents of every dollar goes directly into the programs, directly making a difference in the lives of its members. Their motto is: Changing lives. Creating Community. Today, VALLEYLIFE is humbly turning to its community for financial support so that their organization can continue to provide services to a population of people often forgotten, developmentally disabled adults.

Please show your support by calling in a monthly pledge or sending in a one-time donation. The staff at VALLEYLIFE also welcomes the public to an open house at their facility. Donors will see first-hand how even the most modest financial donation goes a long way, directly touching the lives of those who need immediate help and care.

To learn more about VALLEYLIFE, please visit www.VALLEYLIFEaz.org

Click here to see all recent news from this company

AUSTIN, TX–(Marketwire – August 10, 2010) –  As a recognized leader in the business of medical and radiation oncology, Revenue Cycle Inc. announces a new partnership with The Oncology Group. The affiliation continues a growing trend for Revenue Cycle, known for its broad-based oncology consulting work and education and training services.

As one of the premier cancer care consulting organizations in the nation, The Oncology Group will join the 3 core businesses that are Revenue Cycle: RC Billing for medical practice coding, billing, insurance submissions and AR management; Revenue Cycle consulting services which offer complete audits to measure charge capture accuracy and standards compliance; and NDevor, a healthcare facilities development company.

“We are pleased to add The Oncology Group as an affiliate and look forward to the continued growth of our companies,” says Revenue Cycle Inc. Chief Executive Officer Ron DiGiaimo. “Recognizing a need for a ‘best of the best’ is part of the company culture, and dictates everything Revenue Cycle does on a daily basis; the merger will increase our combination of resources and expertise.”

President of The Oncology Group Marsha Fountain adds, “The Oncology Group will continue its tradition of customized oncology services consulting and strategic planning for community and academic cancer centers. Our relationship with Revenue Cycle Inc., and their position as a key source of thought leadership within the physician practice arena increases both firms’ influence within an integrating cancer services market.”

The combined activities of both companies will continue The Oncology Group’s focus on all aspects of oncology growth and business management. Leaders from both merger partners agree that the strategic alliance will benefit their clients, as hospitals work to create and sustain integrated 21st century cancer centers and physician practices. For more information about Revenue Cycle Inc., please visit www.revenuecycleinc.com. To contact The Oncology Group visit www.theoncologygroup.com.

MUNDELEIN, IL–(Marketwire – August 10, 2010) –  ClearCount Medical Solutions and Medline Industries, Inc. today announced that their newest customers, the VA Pittsburgh Healthcare system, will help prevent retained surgical sponge incidents with the use of the SmartSponge System^®. The SmartSponge System is part of ClearCount’s radio-frequency identification (RFID)-based platform that uniquely identifies each sponge so that they can be easily counted and detected. Medline is the exclusive distributor for the SmartWand-DTX and the SmartSponge System, the only FDA-cleared systems using RFID to both count and locate surgical sponges.

“We are pleased to derive the benefits of such a comprehensive solution for the prevention of retained surgical sponges,” said Mark A. Wilson, M.D., Ph.D. Chief Surgeon and Medical Director of the Surgery Specialty Service Line, VA Pittsburgh. “We use the SmartSponge System to improve patient safety in our ORs with the goal of also improving efficiency. The uniqueness of this RFID platform is its integration of both counting and detection strategies. It is capable of growing with our patient safety initiatives, and we look forward to the future benefits it will provide.”

“The SmartSponge System provides a safety net for human error. Despite the level of experience of staff, individuals are bound to make mistakes. Distractions during counting and the mundane simplicity of ‘counting’ make the inevitability of losing track of a sponge a constant reality. The use of a system that virtually eliminates retained sponge incidents allows us to meet our ethical obligation to our patients,” said William Stevens, RN, BSN, CNOR Nurse Manager OR/PACU Surgery Specialty Service Line, VA Pittsburgh.

The VA Pittsburgh hospital has implemented SmartSponge Systems into its full suite of operating rooms. The national Veterans Health system, which includes 155 medical centers and 842 outpatient clinics, is the largest health care system in the US, with more than 5 million of the 25 million veterans alive today receiving its services.

“We’re pleased to add the VA Pittsburgh to our customer base,” said David Palmer, Chief Executive Officer of ClearCount. “The VA Pittsburgh has shown great leadership in terms of innovation and its commitment to patient safety. We are proud to now be a part of that continued tradition.”

Despite designation as a “never event,” retained items are estimated to occur in one of every 1,000 to 1,500 abdominal surgical procedures, which can lead to hospital inefficiencies, unnecessary costs, serious infections and even death. Hospital infections add an estimated $30.5 billion to the nation’s hospital costs each year. In one study using a retrospective review of medical malpractice claims data from a statewide insurer in Massachusetts, sponge counts had been falsely correct in 76 percent of non-vaginal surgical cases involving retained sponges. Falsely correct sponge counts were attributed to team fatigue, difficult or long operations, sponges “sticking together,” shift changes or procedures with a large number of sponges.

About ClearCount Medical Solutions
ClearCount Medical Solutions is a medical device company focused on patient safety solutions. ClearCount has assembled an extendable RFID-based platform that provides a comprehensive solution to improve efficiency while preventing medical errors, distributed exclusively by Medline. ClearCount Medical Solutions has been recognized with a Popular Science 2009 Best of What’s New Award, and has received additional recognition from TIME and WIRED magazines, the 2009 Wall Street Journal Technology Innovation Award, the International Design Excellence Award (IDEA) and more. ClearCount’s SmartSponge and SmartWand-DTX systems are the only RFID enabled systems for counting and detecting surgical sponges, thereby improving patient and OR safety, enhancing productivity, and reducing cost. To learn more, visit www.clearcount.com.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

ROCKVILLE, MD–(Marketwire – August 10, 2010) –  MarketResearch.com has announced the addition of Wintergreen Research’s new report “Long Term Care and Nursing Home Information Systems Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016” to their collection of Information Technology market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2746054

New long term care information systems have revolutionized the market, creating units that work across the board in long term care situations. This evolution of the software means that clinicians have more flexibility of care decisions, caring for people.

Information systems are emerging as a significant part of the nursing home and long term care delivery systems. All facilities have some kind of automated systems, but this study addresses the industry specific systems that are evolving with industry specific financial management and process integration. Software leverages the efficiency of clinical process in ways that have never become possible before. The electronic patient record can be integrated with financial systems, increasing the efficiency of transmitting services description to the insurance providers.

The ability to capture services delivery electronically at the point of care is central to creating more efficient infrastructure for the providers. The system leverages virtually all the administrative and financial information needed to run a successful home care company. Information can be gathered right from the charts.

The significance of integration systems is not yet realized in nursing home information systems. Collaboration and electronic patient records promise to drive the efficiencies gained from electronic records in to the clinical delivery process, giving caretakers more time to spend with patients. As patients move from one care venue to another, the patient record is going to need to move with them. The hand©held, computer-based system guides home care clinicians through the entire patient care process. Clinicians can use structured record guides. The systems automate reporting.

The fundamental aspect of long term care and nursing home information systems implementation relates to patient treatment flexibility. The ability to be responsive to changing patient conditions is central to the task of controlling nursing home and skilled nursing facility costs. The ability of systems to support flexibility in managing patients to lower cost care delivery sites is anticipated to spur rapid growth of the electronic patient record for these facilities. Long term care and nursing home information systems markets at $225.8 million in 2009 are anticipated to reach $674.9 million by 2016.

Topics covered in the report include…

• Nursing Home and Long Term Care Information Systems Market Description and Market Dynamics
• Long Term Care Information Systems
• Market Shares and Forecasts
• Long Term Care Information System Product Description
• Long Term Care Nursing Home Information Systems Technology
• Long Term Care Nursing Company Profiles

For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2746054

Click here to see all recent news from this company

MENLO PARK, CA–(Marketwire – August 10, 2010) –  Allocade, Inc., the developer of healthcare’s most advanced tools to orchestrate patient flow, today announced the availability of new capabilities in its On-Cue® operations management software suite. On-Cue is powered by an artificial intelligence engine that orchestrates patient flow and automatically adapts to disruptions as they occur, enabling the industry’s only Dynamic Patient Itinerary™ — a time-tagged list of each patient’s preparation and procedure events that adapts in real-time as conditions change. This latest release from Allocade adds options to facilitate communications and manage operations while offloading logistical tasks from clinical staff.

The new capabilities for On-Cue were developed with input from customers. Key features include:

• An enterprise viewer, which allows access to the software suite from anywhere in the hospital, and from any device that is browser-enabled such as smart phones and tablets with access to the hospital’s network.
• Electronic protocoling that enables doctors, nurses and technologists to collaborate seamlessly, not only in preparation for procedures, but while they are actually in progress.
• A portable equipment component that manages the impacts to schedules when staff and equipment go portable in the hospital.

“Allocade continues in its tradition of constant innovation and adaptability with its latest software release,” said Joyce Lasich, Imaging System Administrator, Medical City Dallas Hospital. “We installed the enterprise viewer on all of our front desk computers and we can now ensure a higher quality of patient care and transparency throughout the hospital. We have the ability to view all patients’ imaging schedules with all of the pertinent information for the study with one interface. In addition, caregivers can now send and receive information about the current status of a patient with minimal disruption to workflow, which allows for more time with the patent.”

The immediate and positive response to the new capabilities from customers highlights Allocade’s ongoing commitment to developing software tools that provide powerful capabilities, while remaining simple to use.

Allocade’s Operations Management Software optimizes hospital patient flow for inpatients, outpatients and emergency patients. The software uses technology initially developed to manage workflow on the Hubble Space Telescope by Don Rosenthal, founder and chief technology officer of Allocade. The company’s patented Schedule Repair™ technology augments information already available in Hospital Information Systems (HIS), Radiology Information Systems (RIS) and Electronic Medical Record Systems (EMR) by adding layer of intelligence to these systems.

Allocade and On-Cue were prominently featured in the 2009 issue of NASA Spinoff; an annual book featuring successfully commercialized NASA technology. Allocade was also invited to participate in the May 2010 NASA Spinoff Day on the Hill, where it showcased On-Cue for members of Congress and NASA representatives.  

About Allocade
 Allocade, Inc. was founded in 2004 and is headquartered in Menlo Park, Calif. The company is a healthcare software company that develops tools to intelligently optimize patient flow throughout the hospital enterprise. Allocade’s first product is the On-Cue® Hospital Operations Management solution. The company’s management team includes former top executives from the NASA Ames Research Center, Siemens Medical Systems, Philips Medical Systems, Fujifilm Corporation, and Stentor. For more information, visit http://www.allocade.com.

On-Cue is a registered trademark, and Dynamic Patient Itinerary and Schedule Repair are trademarks of Allocade, Inc.

WINNIPEG, MANITOBA–(Marketwire – Aug. 10, 2010) – DiaMedica Inc. (TSX VENTURE:DMA) today announced the appointment of Dr. Michael Giuffre to the company’s Board of Directors.

Dr. Giuffre is a Clinical Professor of Cardiac Sciences and Pediatrics at the University of Calgary. Dr Giuffre is currently a member on the board’s of the Alberta Medical Association and Unicef Canada. He is a past representative to the board of the Calgary Health Region and is an active participant in the biotechnology business sector.

“Dr. Giuffre’s clinical and business experience, particularly with his extensive cardiovascular background, will add additional depth to our Board,” stated Mr. Rick Pauls, President and CEO of DiaMedica.

“I am pleased to be joining the Board of Directors of DiaMedica at such a progressive time in its history,” stated Dr. Giuffre. “DiaMedica has very promising technology and I look forward to leveraging my experience as the company prepares for exciting and ambitious milestones.”

About Dr. Michael Giuffre

As a Clinical Professor of Cardiac Sciences and Pediatrics at the University of Calgary, Dr Giuffre maintains a portfolio of clinical practice, cardiovascular research, and university teaching. He maintains on-going involvement in both health care administration, and in the biotechnology business sector. Dr Giuffre is Past President of the Calgary and Area Physicians Association (CAPA) and a past representative to the board of the Calgary Health Region. Dr Giuffre holds a BSc in cellular and microbial biology, a PhD candidacy in molecular virology, an MD and an MBA. His Canadian Royal College board certified specialties include Pediatrics, Pediatric Cardiology and a subspecialty in Pediatric Electrophysiology.

As a biotechnology consultant, Dr. Giuffre has been involved with RedSky Inc. (acquired by Research in Motion), MDMI, and MedMira Inc. He is currently on the boards of IC2E Inc and FoodChek Inc. He serves on the Medical Advisory Board of the SADS Foundation and on the boards of Unicef Canada and the Alberta Medical Association. He is also an MD-MP contact for the Canadian Medical Association.

Dr Giuffre has recently received a Certified and Registered Appointment by the American Academy of Cardiology, “Distinguished Fellow of the American Academy of Cardiology,” and in 2005 was awarded “Physician of the Year” by the Calgary Medical Society.

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments for diabetes and neurological disorders. The Company’s type 2 diabetes program is based on a critical liver nerve signaling mechanism involved in enhancing insulin sensitivity after meal consumption. Two of DiaMedica’s products, DM-71 and DM-99, have previously demonstrated human efficacy in lowering blood sugar levels in people diagnosed with type 2 diabetes based on this novel nerve signaling mechanism.

DiaMedica has expanded its DM-199 recombinant protein program into neurological and autoimmune disorders. The Company has demonstrated that DM-99, the naturally occurring form of DM-199, confers neural protection (protects brain cells) and triggers neural stem cell proliferation (creates brain cells) for the treatment of numerous neurological disorders including Alzheimer’s disease. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”. For further information please visit www.diamedica.com.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the prospective Offering and the proceeds from the Offering, the anticipated use of proceeds from the Offering, regulatory approval of the Offering, and our other plans, estimates and expectations, including the completion of our proposed acquisition of Sanomune Inc. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our ability to complete the Offering, the availability of financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. 
Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2008 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of financing for research and development companies, general business and economic conditions, and DiaMedica’s ability to complete its proposed acquisition of Sanomune Inc. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our proposed acquisition of Sanomune Inc. may be found in our press release dated February 18, 2010.

WEINHEIM, GERMANY–(Marketwire – August 10, 2010) – On July 23, 2010 the liver cell preparation by Cytonet GmbH & Co. KG received an Investigational New Drug allowance (IND) from the U.S. Food and Drug Administration (FDA). This is the first time a later stage clinical trial with liver cell therapy can now be started in the US. The FDA-approval is partly based on interim results of an ongoing clinical trial in Germany with neonatal patients suffering from urea cycle disorders (UCD). Cytonet will immediately start the clinical trial SELICA (Safety and Efficacy of Liver Cell Application)-III. The objective of this open, prospective, group-matched, historic-controlled multi-center study is to investigate the safety and efficacy of liver cell therapy in children suffering from UCD. Five therapy centers, as well as 10 centers actively assigning patients and responsible for the after-care, are participating in the SELICA-III trial. 

This study is the second clinical study on liver cell therapy in children suffering from UCD. The first trial, SELICA-II, has been running in Germany for approximately 1 year. SELICA-III comprises a six-month treatment and observation phase and a subsequent 18-month follow-up. The study includes infants, toddlers and children up to the age of five, who are suffering from the most severe forms of the following UCDs: ornithine transcarbamylase (OTC) deficiency, carbamoyl­phosphate synthetase I (CPS I) deficiency or argininosuccinate-synthetase (ASS) deficiency, also called citrullinemia. Cytonet would like to acknowledge the National Urea Cycle Disorders Foundation for its assistance during the development of the program. For more information about urea cycle disorders, visit the National Urea Cycle Disorders Foundation at www.nucdf.org.

About urea cycle disorders and liver cell therapy
UCDs are severe and life-threatening disorders of the ammonia (NH3) metabolism of the liver. These include carbamoylphosphate synthetase I (CPS) deficiency, N-acetylglu­tamate-synthetase (NAGS) deficiency, ornithine-transcarbamylase (OTC) deficiency, argininosuccinate-synthetase (ASS) deficiency — also known as citrullinemia, arginino­succinate-lyase (ASL) deficiency and arginase 1 deficiency (hyper­argi­ninemia). UCDs are based on disorders of 6 known enzymes that are involved in NH3-detoxification. In UCD-patients, the neurotoxic NH3 is not metabolized into urea and excreted. Instead, it accumulates in the blood and tissue. Depending on the severity of the disease, it leads to massive damage of the nerves and the brain, and can be fatal. Children who remain untreated rarely have a normal physical and mental development.

The only currently available cure is the transplantation of a whole liver or a liver lobe. However, this treatment is highly problematic for very young children and neonatal patients. Additionally, suitable organs available for transplantation are very rare. A therapy using isolated and processed liver cells from non-transplantable donated livers (manufactured under GMP standards) has been investigated and further developed over the past years. Cytonet is working in close cooperation with internationally leading neonatal and pediatric metabolism centers. The overall goal is an effective compensation of the metabolism disorder by means of the infusion of healthy, fully metabolism-competent human liver cells into the portal vein, subsequently engrafting in the liver of the child with the disorder.

About Cytonet
The Cytonet Group is an international biotechnology company with sites in Weinheim, Heidelberg and Hannover, Germany and Durham, NC, USA. Currently Cytonet has 60 employees. The company develops, produces and markets cell-therapeutic products for many diseases. In the process developed by Cytonet, liver cells from donated livers are gently isolated and cleaned up in a complex procedure. The donor livers, which are obtained from Organ Procurement Organizations in the United States, are unsuitable for organ transplantation. Additionally, Cytonet provides blood stem cell and bone marrow preparations for the therapy of leukemia and other malignant diseases. Managing directors are Dr. Wolfgang Rüdinger and Dipl.-Kfm. (MBA) Michael J. Deissner. Cytonet was founded by the demerger of the Cell Therapy department from the Roche Group in April 2000. The Dietmar Hopp family owns the majority of shares.

NEW YORK, NY and TORONTO–(Marketwire – August 10, 2010) –  A diverse marketing mix that includes and addresses communication preferences of readers is essential to any marketing or advertising campaign, and print marketing and direct mail still remain an integral part of that mix, says Patient News, a leading dental marketing solutions company.

“Statistics show that most marketers have found that online channels demonstrate greater value when distributed in conjunction with direct mail applications, reinforcing the value of print in the marketing mix,” said Karen Galley, President of Patient News.

Baby Boomers, who have an annual spending power of $2.1 trillion and account for upwards of 60% of all healthcare spending, actively shop through the mail and keep mail pieces for future reference. According to a research study by JWT BOOM and ThirdAge Inc., 90% of Baby Boomer women surveyed have seen a print ad and later visited the online site. As women make more than 85% of all healthcare buying decisions, this adds up to significant business that can be attributed to print marketing such as newsletters, direct mail or custom postcards.

In addition, the coveted 18-49 consumer group welcomes, reads and responds to printed materials. Close to 90% of this group sort through mail immediately, nearly 80% read direct mail advertising, and about 70% use coupons received in the mail.

“Print is an amazing online traffic generator, and it delivers consistent response rates,” said Galley. “People are more willing to try new brands than ever before, and those over 50 years old, the primary target for most of our dentists, are more likely than any other group to read and respond to direct mail pieces.”

For additional information on dental newsletters, variable data services, dental postcards, printed or e-dental advertising from Patient News call 800.667.0268 or visit www.Patientnews.com.

To read more on this topic, visit: http://www.patientnews.com/pressreleases/print-dental-marketing-in-mix.html.

About Patient News:

Patient News is North America’s most comprehensive and innovative provider of direct mail, newsletters, postcards, email newsletters, and referral cards. Founded in 1992, the company produces award-winning healthcare and dental marketing products in Canada, the United States, and the United Kingdom.

Click here to see all recent news from this company